AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$SIBN

Maheshwari Anshul sold $81K of SIBN

Maheshwari Anshul (Chief Op & Financial Officer) sold 3,247 shares of SI-BONE, Inc. (SIBN) at $25.00 on 2026-11-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maheshwari Anshul
Published Nov 6, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SIBN
Bearish
medium confidence
Mentioned
$SIBN
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIBNBearishLow
01

Why it matters

The disclosed sale is small and unlikely to affect price materially, but traders may monitor for any pattern of insider disposals.

02

Market read

A modest insider sell with limited trading relevance.

03

What to watch

The officer's remaining stake remains sizable, suggesting continued confidence.

Relevance 2/10Novelty 2/10Timing: after-hours filing

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates pre‑arranged sales.

Company-level read

Ticker impact

$SIBNBearishMedium confidence
Context

Chief Operating & Financial Officer sold 3,247 shares for $81,175 via a 10b5‑1 plan, reducing his holdings to 211,250 shares.

Expected impact

potential slight downside as market prices in the insider sell

Evidence & confidence

The sale is modest in size relative to the company's market cap and likely will not move the stock significantly, but it may signal a neutral to mildly negative sentiment.

Market effects

Sector

No material impact on the orthopedic device sector.

Regional

Limited to U.S. investors tracking insider activity.

Global

None

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing and not indicative of company fundamentals.

Key entities

  • person
    Maheshwari Anshul

    Chief Operating & Financial Officer of SI‑BONE, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SIBN insider trading history →

Related articles

$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

rttnews.com
$SIBNMed

SI-BONE (SIBN) Q3 2026 Earnings Call Transcript

SI-BONE (SIBN) reported Q3 2026 earnings, highlighting 27% international revenue growth and 32% adjusted EBITDA increase. The company launched iFuse Granite Onyx, expanding its market to 650,000 procedures and $5B opportunity. Onyx targets spinal fusion failure points, with early demand exceeding expectations. New DRGs and reimbursement enhancements support growth. The company expects 20%+ revenue growth in Q4 2026.

finance.yahoo.com
$SIBNMed

SiBone Q3 Earnings Call Highlights

SiBone (SIBN) reported Q3 earnings, highlighting strong demand for its Onyx platform, which targets a $1.5B market. Gross profit rose 13.7% to $44.2M, with gross margin at 79.3%. Net loss narrowed to $3.6M. The company reaffirmed 2026 revenue guidance of $231M-$233M and expects Q4 momentum from physician growth and new products.

finance.yahoo.com